Search

This article provides an overview of the role of DNA methylation in cancer, focusing on its functions, therapy implications, and potential future developments. Abnormal DNA methylation is commonly observed in cancer and is considered an important indicator of malignant progression. The article discusses the role of DNA methyltransferases (DNMTs) in both hematologic malignancies and solid tumors. It also highlights the potential for targeted therapy by inhibiting DNA methylation. The article emphasizes the importance of identifying key methylation changes in different types of cancer through pan-cancer analyses to identify relevant molecular targets. Additionally, it explores the potential of combining DNA methylation targeting with immune therapy for future tumor treatment development. However, the article acknowledges limitations in current research, such as the focus on DNA methylation in promoter regions and the need for comprehensive multi-omics analyses. Overall, the article underscores the significance of DNA methylation in cancer and the potential for personalized clinical treatments. [Extracted from the article]